Core Insights - The medical device sector experienced a slight increase of 0.39% on September 29, with Tianzhihang leading the gains [1] - The Shanghai Composite Index closed at 3862.53, up 0.9%, while the Shenzhen Component Index closed at 13479.43, up 2.05% [1] Medical Device Sector Performance - Tianzhihang (688277) saw a closing price of 18.47, with a rise of 7.70% and a trading volume of 172,400 shares, amounting to a transaction value of 315 million yuan [1] - Jimin Health (603222) closed at 11.30, up 5.51%, with a trading volume of 494,600 shares and a transaction value of 556 million yuan [1] - Dongxing Medical (301290) closed at 29.32, increasing by 4.86%, with a trading volume of 99,500 shares and a transaction value of 29.67 million yuan [1] - Other notable performers included Sainuo Medical (688108) with a 4.82% increase and a closing price of 27.83, and Tianchen Medical (688013) with a 3.89% increase, closing at 59.52 [1] Capital Flow Analysis - The medical device sector saw a net inflow of 85.63 million yuan from institutional investors, while retail investors contributed a net inflow of 46.52 million yuan [2] - However, speculative funds experienced a net outflow of 132 million yuan [2] Individual Stock Capital Flow - Sainuo Medical (688108) had a net inflow of 111 million yuan from institutional investors, but a net outflow of 68.66 million yuan from speculative funds [3] - Mairui Medical (300760) also saw a significant net inflow of 107 million yuan from institutional investors, with a net outflow of 76.49 million yuan from speculative funds [3] - Jimin Health (603222) had a net inflow of 53.49 million yuan from institutional investors, while speculative funds saw a net outflow of 43.40 million yuan [3]

Core Viewpoint - Shanghai Zhijiang Biological Technology Co., Ltd. has established a special account for the management of raised funds and signed a regulatory agreement to ensure the proper use of these funds for its investment projects, specifically the "Japanese Intelligent Manufacturing Project" [3][5]. Fundraising Basic Information - The company was approved for its initial public offering (IPO) on November 27, 2020, by the China Securities Regulatory Commission, allowing it to issue 48.676088 million shares at a price of RMB 43.22 per share, raising a total of RMB 2,103.78 million, with a net amount of RMB 1,942.32 million after deducting issuance costs [2]. Special Account Opening and Regulatory Agreement - A special account for the raised funds has been opened at China Merchants Bank, specifically for the Japanese Intelligent Manufacturing Project, with the account balance being RMB 0 as of September 25, 2025 [3][4]. - The agreement involves three parties: the company, China Merchants Bank, and Guotai Junan Securities Co., Ltd., to ensure compliance with relevant laws and protect investor rights [3][5]. Main Contents of the Regulatory Agreement - The special account is exclusively for the storage and use of funds related to the designated project and cannot be used for other purposes [3][4]. - Guotai Junan Securities, as the sponsor, is responsible for supervising the use of the raised funds and must conduct at least biannual inspections of the account [5][6]. - The agreement stipulates that if the company withdraws more than RMB 500 million or 20% of the net raised funds within 12 months, it must notify the sponsor and provide a detailed expenditure list [6][7]. Agreement Validity and Termination - The agreement becomes effective upon signing and remains valid until all funds are spent and the account is closed [6][7]. - If the agreement is terminated early, the company must sign a new agreement within one month and announce it promptly [6][7].

证券代码：688317 证券简称：之江生物 公告编号：2025-054 上海之江生物科技股份有限公司 关于开立募集资金专户并签订募集资金专户监管协 议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 募集资金基本情况 上海之江生物科技股份有限公司（以下简称"公司"）首次公开发行股票并 在科创板上市的注册申请于 2020 年 11 月 27 日经中国证券监督管理委员会同意 注册（证监许可[2020]3214 号《关于同意上海之江生物科技股份有限公司首次 公开发行股票注册的批复》）。公司获准向社会公开发行人民币普通股（A 股）股 票 4,867.6088 万股，每股发行价格人民币 43.22 元，募集资金合计 210,378.05 万元，扣除发行费用后，实际募集资金净额为 194,232.16 万元。上述募集资金 到位情况已经中汇会计师事务所（特殊普通合伙）审验，并由其出具《验资报告》 （中汇会验[2021]第 0039 号）。 二、 募集资金专户的开立情况及《募集资金专户存储三方监管协议》的签 订情况 甲方：上海 ...

证券代码：688317 证券简称：之江生物 公告编号：2025-053 上海之江生物科技股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2025 年 9 月 25 日（星期四）至 10 月 9 日（星期四）16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过上海之江生物科技股份 有限公司（以下简称"公司"）邮箱 info@liferiver.com.cn 进行提问。公司将 在说明会上对投资者普遍关注的问题进行回答。 公司已于 2025 年 8 月 29 日发布公司 2025 年半年度报告，为便于广大投资 者更全面深入地了解公司 2025 年半年度经营成果、财务状况，公司计划于 2025 年 10 月 10 日（星期五）9:00-10:00 举行 2025 年半年度业绩说明会，就投资者 关心的问题进行交流。 一、 说明会类型 （三） 会议召开方式：上证路演中心网络互动 三、 参加人员 董事长、总经理：邵俊斌先生 副总经理、 ...

Core Viewpoint - Zhijiang Biotech experienced a decline of 5.03% on September 23, with a stock price of 22.86 CNY per share and a total market capitalization of 4.393 billion CNY [1] Company Overview - Zhijiang Biotech, established on April 18, 2005, and listed on January 18, 2021, is located in Minhang District, Shanghai. The company specializes in the research, production, and sales of molecular diagnostic reagents and equipment [1] - The revenue composition of the company includes 86.47% from nucleic acid testing kits, 11.99% from other products, and 1.54% from molecular diagnostic instruments [1] Shareholder Information - Among the top ten circulating shareholders of Zhijiang Biotech, a fund under Rongtong Fund holds 1.5 million shares, unchanged from the previous period, representing 0.78% of the circulating shares. The estimated floating loss today is approximately 1.815 million CNY [2] - The Rongtong Health Industry Flexible Allocation Mixed A/B fund (000727) was established on December 25, 2014, with a current scale of 2.074 billion CNY. Year-to-date returns are 19.74%, ranking 4408 out of 8172 in its category, while the one-year return is 46.63%, ranking 3544 out of 7995 [2] Fund Manager Information - The fund manager of Rongtong Health Industry Flexible Allocation Mixed A/B is Wan Minyuan, who has been in the position for 9 years and 31 days. The total asset scale of the fund is 5.629 billion CNY, with the best return during his tenure being 155.09% and the worst being -17.06% [3]

本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海之江生物科技股份有限公司（以下简称"公司"）产品猴痘病毒核酸检 测试剂盒（荧光 PCR 法）于近日收到世界卫生组织（以下简称"WHO"）通知， 于 2025 年 9 月 17 日被列入为 WHO 应急使用清单（英文全称"Emergency Use Listing"，以下简称"EUL"）。现将具体情况公告如下： | 产品名称 | Monkeypox Virus Lyo-PCR Kit | | --- | --- | | | 猴痘病毒核酸检测试剂盒（荧光 PCR 法） | | 申请号 | MPXV-13393-139-00 | | 产品编码 | W-ZD-0580-02-48A,W-ZD-0580-02-96A | | 批准时间 | 2025 年 9 月 17 日 | | 使用期限 | 如无特殊情况，该产品的采购期限为 1 年 | | | 公司将持续按照 WHO 法规和指南满足 WHO EUL 项目的要求。若不 | | 其他 | 能满足相关条件，则产品可能面临 WHO 的矫正措 ...

Core Viewpoint - The company, Zhijiang Biotech (688317.SH), has received notification from the World Health Organization (WHO) that its monkeypox virus nucleic acid test kit (using fluorescent PCR method) will be included in the WHO Emergency Use Listing (EUL) by September 17, 2025, indicating WHO's recognition and endorsement of the product [1] Group 1 - The inclusion of the monkeypox product in the WHO EUL provides a basis for procurement for WHO member countries and potential buyers [1] - This recognition is expected to facilitate the promotion and sales of the company's monkeypox products in relevant overseas markets [1]

人民财讯9月18日电，之江生物(688317)9月18日公告，公司产品猴痘病毒核酸检测试剂盒(荧光PCR法) 于近日收到世界卫生组织(简称"WHO")通知，于2025年9月17日被列入为WHO应急使用清单。 ...

Core Viewpoint - The company Zhijiang Biotech (688317.SH) has received notification from the World Health Organization (WHO) that its monkeypox virus nucleic acid test kit (fluorescent PCR method) has been included in the WHO Emergency Use Listing (EUL) effective September 17, 2025, indicating recognition and endorsement from WHO [1] Group 1 - The inclusion of the product in the WHO EUL provides a basis for procurement for WHO member countries and potential buyers [1] - This recognition is expected to facilitate the promotion and sales of the company's monkeypox products in relevant overseas markets [1]

上述产品被列入WHO EUL，表明WHO对公司产品的认可和肯定，可为WHO成员国和各意向采购方提 供采购依据，对公司猴痘产品在相关海外市场的推广和销售起到推动作用。 智通财经APP讯，之江生物(688317.SH)发布公告，公司产品猴痘病毒核酸检测试剂盒(荧光PCR法)于近 日收到世界卫生组织(以下简称"WHO")通知，于2025年9月17日被列入为WHO应急使用清单(英文全 称"Emergency Use Listing"，以下简称"EUL")。 ...